<DOC>
	<DOCNO>NCT00050102</DOCNO>
	<brief_summary>The objective study determine safety activity profile multiple dose MDX-010 , determine whether addition cytotoxic chemotherapy ( decarbazine [ DTIC ] ) augment effect MDX-010 patient chemotherapy na√Øve metastatic melanoma tolerable toxicity profile .</brief_summary>
	<brief_title>Comparison Study MDX-010 ( CTLA-4 ) Alone Combined With DTIC Treatment Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Inclusion Criteria Clinical diagnosis unresectable metastatic melanoma . No prior chemotherapy melanoma , chemotherapy malignancy within 5 year least 4 week since treatment ( surgery , radiation , immunotherapy ) melanoma . Exclusion Criteria Patients exhibit follow condition screen eligible admission study : Any prior malignancy , except follow : adequately treat basal squamous cell skin cancer superficial bladder cancer , cancer patient diseasefree &gt; =5 year . Active autoimmune disease . Active infection require therapy , chronic active HBV HCV , confirm reactivity HIV test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>